Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Samsung Medical Center
Age
20–any
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
pathologically confirmed prostate cancer within 6 months for study enrollment
Clincally enlarged pelvic lymph node ((short axis 0.5 cm ≤) in imaging studies (CT, MRI, PET-CT) at diagnosis and partial response or complete remission of enlarged lymph nodes according to RECIST v1.1 after hormonal therapy for 2-3 months 3. age 20 ≤ 4. ECOG performance status 0-1 5. Optimal hematologic profiles within 6 months for study enrollment
Absolute neutrophil count (ANC) ≥ 1500 cells/mm3
Platelets ≥ 50,000 cells/mm3
Hemoglobin ≥ 8.0 g/dl 6. Optimal kidney function within 6 months for study enrollment
Creatinine \< 2.0 ng/dL 7. Optimal liver functions within 6 months for study enrollment
total bilirubin \< 1.5 X maximum normal value
alanine aminotransferase or aspartate aminotransferase \< 2.5 X maximum normal value
You may not be if
1. combined with distant metastasis (retroperitoneal lymph node, bone,...)
2. previous history of antiandrogen therapy within 6 months of study enrollment
3. previous history of definitive prostate cancer treatment such as prostatectomy
4. previous history of pelvic radiotherapy
5. previous history of other cancer treatment except for skin cancer and theroid cancer
Clareo Health | COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer
